Jason B. Daly, Senior Vice President and Chief Legal Officer at Amneal Pharmaceuticals, Inc. (NYSE:NASDAQ:AMRX), has sold 13,665 shares of the company's Class A Common Stock. The transaction, which took place on November 21, 2024, was executed at a price of $8.40 per share, resulting in a total value of $114,786. Following this sale, Daly no longer holds any shares in the company.
In other recent news, Amneal Pharmaceuticals has resubmitted a New Drug Application (NDA) for its dihydroergotamine (DHE) autoinjector, intended for the acute treatment of migraines and cluster headaches in adults. This move follows approval from the U.S. Food and Drug Administration (FDA) for exenatide, a generic injectable glucagon-like peptide-1 (GLP-1) agonist used to improve glycemic control in adults with type 2 diabetes mellitus. Additionally, the company reported a 13% increase in third-quarter revenue, reaching $702 million, outpacing the Street's expectations. This growth was driven by strategic initiatives such as the launch of CREXONT for Parkinson's disease and a partnership with Metsera for obesity treatment. Piper Sandler, a financial services firm, upgraded its stock price target for Amneal Pharmaceuticals from $9.00 to $11.00, maintaining its Overweight rating on the stock. Looking ahead, Amneal anticipates healthcare distribution revenues to exceed $700 million by 2025, with international expansion adding an additional $50-100 million by 2027. These recent developments suggest clear prospects for sustained growth, according to Piper Sandler.
InvestingPro Insights
As Jason B. Daly, Senior Vice President and Chief Legal Officer at Amneal Pharmaceuticals, Inc. (NYSE:AMRX), divests his entire stake in the company, it's worth examining the broader financial context of this transaction.
Amneal Pharmaceuticals has shown strong performance recently, with a remarkable 86.97% price total return over the past year. This aligns with an InvestingPro Tip highlighting the company's high return over the last year. The stock's current price of $8.32 is 88.55% of its 52-week high, indicating sustained investor confidence.
Despite the positive price momentum, it's important to note that Amneal was not profitable over the last twelve months, as pointed out by another InvestingPro Tip. However, analysts predict the company will be profitable this year, which could explain the market's optimistic outlook.
From a valuation perspective, Amneal's market capitalization stands at $2.6 billion. The company's revenue for the last twelve months as of Q3 2024 was $2.68 billion, with a notable revenue growth of 12.32% during this period. This growth trend is further supported by a 13.29% quarterly revenue increase in Q3 2024.
For investors seeking more comprehensive analysis, InvestingPro offers 11 additional tips for Amneal Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.